China SXT Pharmaceuticals (SXTC) is trading down at $2.08 (-13.69%), as of the latest quote. It operates in the Health Care sector.
| FY2017Mar 2017 | FY2018Mar 2018 | FY2019Mar 2019 | FY2020Mar 2020 | FY2021Mar 2021 | FY2022Mar 2022 | FY2023Mar 2023 | FY2024Mar 2024 | FY2025Mar 2025 | FY2026Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $4.88M | $7.02M | $7.01M | $5.16M | $4.78M | $2.60M | $1.97M | $1.93M | $1.74M | $1.14M |
| Growth (year over year) | — | +43.8% | −0.1% | −26.4% | −7.5% | −45.5% | −24.2% | −2.2% | −9.7% | −34.6% |
| Gross profit | $2.31M | $3.40M | $4.61M | $2.70M | $2.84M | $1.25M | $426.3K | $554.0K | $367.4K | $248.7K |
| Gross margin | 47.4% | 48.5% | 65.8% | 52.4% | 59.4% | 48.1% | 21.6% | 28.7% | 21.1% | 21.9% |
| Operating income | $1.60M | $1.63M | $1.77M | −$1.34M | −$2.20M | −$5.19M | −$5.61M | −$2.52M | −$2.68M | −$7.12M |
| Operating margin | 32.8% | 23.3% | 25.2% | −26.0% | −46.0% | −199.4% | −284.4% | −130.4% | −154.0% | −625.9% |
| Net income | $1.19M | $1.19M | $1.54M | −$10.3M | −$2.75M | −$5.74M | −$5.93M | −$3.10M | −$3.30M | −$6.21M |
| Net margin | 24.3% | 16.9% | 22.0% | −199.3% | −57.5% | −220.4% | −301.0% | −160.7% | −189.8% | −545.2% |
| EPS (diluted) | $11.80 | $11.80 | $15.00 | $66560.00 | −$763.80 | −$1103.34 | −$177.84 | −$4285.66 | −$348.17 | −$9.13 |
| Balance sheet | ||||||||||
| Cash and equivalents | $65.6K | $657.8K | $9.29M | $7.29M | $13.3M | $15.5M | $17.4M | $12.1M | $18.1M | $28.2M |
| Total assets | — | $7.66M | $17.5M | $21.7M | $34.5M | $33.5M | $29.6M | $23.1M | $21.7M | $34.8M |
| Total liabilities | — | $4.37M | $6.36M | $12.3M | $18.6M | $17.1M | $14.9M | $9.20M | $6.22M | $5.05M |
| Long-term debt | — | — | $41.7K | $36.5K | $6.29K | — | $117.9K | $117.1K | $96.3K | $644.4K |
| Shareholders' equity | $1.85M | $3.29M | $11.1M | $9.40M | $16.0M | $16.1M | $14.7M | $13.9M | $15.4M | $29.7M |
| Cash flow | ||||||||||
| Operating cash flow | $293.0K | $1.92M | $239.2K | $934.2K | −$1.32M | $268.3K | −$80.8K | −$1.93M | −$2.35M | −$4.02M |
| Capital expenditure | $179.2K | $436.0K | $535.8K | $130.8K | — | — | — | $7.06K | $2.02K | — |
| Free cash flow | $113.9K | $1.48M | −$296.6K | $803.4K | — | — | — | −$1.94M | −$2.35M | — |
From China SXT Pharmaceuticals's 20-F and 6-K filings with the SEC; its fiscal year ends in March. Each period shows the latest figure the company has reported for it, including restatements. Per-share figures are per ordinary share, which is not always the share traded in the US: an ADS can stand for several, or for part of one. Filings on SEC EDGAR →
No recent news mentioning China SXT Pharmaceuticals in our feed yet.